Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

378 matching registry records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 18:03 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableRecruitingOBSERVATIONAL

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

ClinicalTrials.gov · NCT05663515 · Registry updated: 2026-09-24

Condition / research focus: Pancreatic Cancer
Sponsor: AstraZeneca
Countries with listed sites: Denmark · Finland · France · Norway · Spain · Sweden · United Kingdom
Registry dates and results: Start: 2024-09-30. Completion: 2026-10-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: BYETTA, BYDUREON/BYDUREON BCise
Non-GLP-1 RA based glucose lowering drugs (drug) — also listed as: Insulin/analogues (excl. A10AE54, A10A56), Biguanide, Sulfonylurea, Sulfonamide (heterocycl.), combined oral GLD (excl. DPP-4i), Alpha glucose inhib., Thiazolidinedione, SGLT2i, Oth. GLD excl. insulin

Where the study takes place — 8 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Research Site
Copenhagen, Denmark
Site recruitment: Recruiting
Research Site
Helsinki, Finland
Site recruitment: Recruiting
Research Site
Paris, France
Site recruitment: Recruiting
Research Site
Bergen, Norway
Site recruitment: Recruiting
Research Site
Barcelona, Spain
Site recruitment: Recruiting
Research Site
Vänersborg, Sweden
Site recruitment: Recruiting
Research Site
Edinburgh, United Kingdom
Site recruitment: Recruiting
Research Site
London, United Kingdom
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow

ClinicalTrials.gov · NCT01988545 · Registry updated: 2026-09-15

Condition / research focus: Healthy
Sponsor: Zealand University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2013-11-01. Completion: 2014-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

1,5 nmol/kg,GLP-1 sc injection (other) — also listed as: native GLP-1
1,5 nmol/kg GLP-1 9-36amide, sc injection (other)
Exendin-4 ;10 ug,sc injection (other)
saline (other)

Where the study takes place — 1 listed sites

Køge Hospital
Køge, State..., Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization

ClinicalTrials.gov · NCT07808879 · Registry updated: 2026-09-09

Condition / research focus: Insulinoma
Sponsor: Peking Union Medical College Hospital
Countries with listed sites: China
Registry dates and results: Start: 2026-10-01. Completion: 2027-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

[68Ga]Ga-HBED-CC-PEG6-exendin-4 PET/CT (diagnostic_test) — also listed as: 68Ga-HBED-CC-PEG6-exendin-4
[68Ga]Ga-HBED-CC-exendin-4 PET/CT (diagnostic_test) — also listed as: 68Ga-HBED-CC-exendin-4

Where the study takes place — 1 listed sites

Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

ClinicalTrials.gov · NCT06725693 · Registry updated: 2026-09-08

Condition / research focus: GLP1-R-related Disease; Tumor; Insulinoma; Positron Emission Tomography
Sponsor: Tianjin Medical University
Countries with listed sites: China
Registry dates and results: Start: 2019-02-01. Completion: 2027-11-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

18F/68Ga-Exendin 4 (diagnostic_test)

Where the study takes place — 3 listed sites

The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China
Site recruitment: Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Site recruitment: Recruiting
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableActive, not recruitingOBSERVATIONAL

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

ClinicalTrials.gov · NCT05220917 · Registry updated: 2026-08-13

Condition / research focus: Cardiovascular Events; Type2 Diabetes; Renal Disease
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2021-08-01. Completion: 2027-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SGLT2 inhibitor (drug) — also listed as: CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE
DPP-4 inhibitor (drug) — also listed as: ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE
GLP-1RA (drug) — also listed as: INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE, SEMAGLUTIDE, ALBIGLUTIDE, EXENATIDE MICROSPHERES, EXENATIDE
2nd generation SU (drug) — also listed as: PIOGLITAZONE HCL/GLIMEPIRIDE, ROSIGLITAZONE MALEATE/GLIMEPIRIDE, GLIPIZIDE/METFORMIN HCL, GLYBURIDE,MICRONIZED, GLYBURIDE/METFORMIN HCL, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE

Where the study takes place — 1 listed sites

Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

ClinicalTrials.gov · NCT07702461 · Registry updated: 2026-07-24

Condition / research focus: Obesity & Overweight; Diabetes (DM)
Sponsor: Ohio State University
Countries with listed sites: United States
Registry dates and results: Start: 2026-06-12. Completion: 2027-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon-Like Peptide-1 Agonist (GLP-1) (drug) — also listed as: GLP-1RA

Where the study takes place — 1 listed sites

The Ohio State University
Columbus, Ohio, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

ClinicalTrials.gov · NCT07497399 · Registry updated: 2026-07-17

Condition / research focus: Multiple Sclerosis
Sponsor: Johns Hopkins University
Countries with listed sites: United States
Registry dates and results: Start: 2026-04-28. Completion: 2030-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NLY01 (drug)
Placebo (drug)

Where the study takes place — 2 listed sites

Johns Hopkins University
Baltimore, Maryland, United States
Site recruitment: Recruiting
Mount Sinai School of Medicine
New York, New York, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

ClinicalTrials.gov · NCT05356104 · Registry updated: 2026-06-05

Condition / research focus: Cerebral Small Vessel Disease
Sponsor: Chinese University of Hong Kong
Countries with listed sites: China · Hong Kong
Registry dates and results: Start: 2022-05-25. Completion: 2027-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug) — also listed as: Bydureon BCise, Ozempic

Where the study takes place — 2 listed sites

First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Site recruitment: Recruiting
Chinese University of Hong Kong
Hong Kong, Hong Kong
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy

ClinicalTrials.gov · NCT02860923 · Registry updated: 2026-05-22

Condition / research focus: Craniopharyngiomas; Hypothalamic Obesity
Sponsor: University Hospital, Bordeaux
Countries with listed sites: France
Registry dates and results: Start: 2017-01-11. Completion: 2018-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug)
Placebo (drug)

Where the study takes place — 11 listed sites

CHU d'Angers
Angers, France
Site recruitment: Not reported
CHU de Brest
Brest, France
Site recruitment: Not reported
CHU de Grenoble
Grenoble, France
Site recruitment: Not reported
CHU de Lyon
Lyon, France
Site recruitment: Not reported
APHM
Marseille, France
Site recruitment: Not reported
Hôpital Bicêtre
Paris, France
Site recruitment: Not reported
Hôpital Cochin
Paris, France
Site recruitment: Not reported
Hôpital Européen Georges Pompidou
Paris, France
Site recruitment: Not reported
Hôpital Pitié Salpétrière (APHP)
Paris, France
Site recruitment: Not reported
Hôpital Haut-Lévêque
Pessac, France
Site recruitment: Not reported
CHU de Toulouse
Toulouse, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics

ClinicalTrials.gov · NCT02042664 · Registry updated: 2026-05-07

Condition / research focus: Obesity; Diabetes
Sponsor: Assistance Publique Hopitaux De Marseille
Countries with listed sites: France
Registry dates and results: Start: 2011-01. Completion: 2015-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

BYETTA treatment (drug)
Metformine (drug)

Where the study takes place — 1 listed sites

Assistance Publique Hopitaux de Marseille
Marseille, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

ClinicalTrials.gov · NCT04232969 · Registry updated: 2026-05-06

Condition / research focus: Parkinson's Disease
Sponsor: University College, London
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2020-01-20. Completion: 2024-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide extended release 2mg (Bydureon) (drug)

Where the study takes place — 1 listed sites

University College London Hospital
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

ClinicalTrials.gov · NCT05482789 · Registry updated: 2026-04-20

Condition / research focus: Gestational Diabetes
Sponsor: Maisa N. Feghali, MD
Countries with listed sites: United States
Registry dates and results: Start: 2023-04-12. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug)

Where the study takes place — 1 listed sites

Magee Womens Hospital of UPMC
Pittsburgh, Pennsylvania, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3Active, not recruitingINTERVENTIONAL

Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

ClinicalTrials.gov · NCT00679042 · Registry updated: 2026-04-06

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: CellTrans Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2007-09-05. Completion: 2026-06-14 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Islets of Langerhans transplantation (biological) — also listed as: Islets of Langerhan (Islets), Basiliximab (Simulect®), Tacrolimus (Prograf®), Sirolimus (Rapamune®), Etanercept(Enbrel®), Exenatide (Byetta®)

Where the study takes place — 1 listed sites

University of Illinois at Chicago Medical Center
Chicago, Illinois, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1RecruitingINTERVENTIONAL

A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT07347080 · Registry updated: 2026-04-06

Condition / research focus: T2DM
Sponsor: The First Affiliated Hospital of Henan University of Science and Technology
Countries with listed sites: China
Registry dates and results: Start: 2026-01-20. Completion: 2026-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059）） (drug)

Where the study takes place — 1 listed sites

The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Exenatide for Smoking Cessation and Prevention of Weight Gain

ClinicalTrials.gov · NCT05610800 · Registry updated: 2026-03-23

Condition / research focus: Smoking Cessation; Weight Gain
Sponsor: The University of Texas Health Science Center, Houston
Countries with listed sites: United States
Registry dates and results: Start: 2022-12-07. Completion: 2026-03-10 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide 2 milligram (mg) Injection (drug) — also listed as: Bydureon
Placebo (drug)
Nicotine patch (drug)
Smoking Cessation Counseling (behavioral)

Where the study takes place — 2 listed sites

Michael E. DeBakey VA Medical Center
Houston, Texas, United States
Site recruitment: Not reported
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1WithdrawnINTERVENTIONAL

Exenatide For Reducing the Reinforcing Effects of Cocaine

ClinicalTrials.gov · NCT06252623 · Registry updated: 2026-03-13

Condition / research focus: Cocaine Use Disorder
Sponsor: Christopher D. Verrico
Countries with listed sites: United States
Registry dates and results: Start: 2024-08-01. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Bydureon
Placebo (drug) — also listed as: saline

Where the study takes place — 1 listed sites

Michael E. DeBakey VA Medical Center
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

ClinicalTrials.gov · NCT02251431 · Registry updated: 2026-02-19

Condition / research focus: Type 2 Diabetes Mellitus; Chronic Kidney Disease; Left Ventricular Diastolic Dysfunction
Sponsor: Baylor Research Institute
Countries with listed sites: United States
Registry dates and results: Start: 2015-11. Completion: 2019-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

BYDUREON (drug)
Placebo (drug) — also listed as: Matching placebo subcutaneous injection

Where the study takes place — 1 listed sites

Baylor Scott and White Research Institute- Baylor Heart and Vascular Hospital
Dallas, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)

ClinicalTrials.gov · NCT04897802 · Registry updated: 2026-01-20

Condition / research focus: Hypopituitarism; Central Diabetes Insipidus; Panhypopituitarism; Psychological Disorder; Social Isolation; Hypothalamic Diseases; Pituitary Diseases; Oxytocin Deficiency
Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Countries with listed sites: Spain
Registry dates and results: Start: 2021-09-13. Completion: 2024-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Experimental: GLP1-RA (exenatide) administration (drug) — also listed as: exenatide administration
Control: Placebo administration (drug) — also listed as: placebo administration (sodium chloride)

Where the study takes place — 1 listed sites

Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Clinical Study of 18F-Exendin-4 in Insulinoma

ClinicalTrials.gov · NCT07340437 · Registry updated: 2026-01-15

Condition / research focus: Insulinoma
Sponsor: Sichuan Provincial People's Hospital
Countries with listed sites: China
Registry dates and results: Start: 2023-02-01. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Department of Endocrinology and Department of Nuclear Medicine, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072
Chengdu, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2WithdrawnINTERVENTIONAL

Diabetes Islet Preservation Immune Treatment

ClinicalTrials.gov · NCT02586831 · Registry updated: 2026-01-15

Condition / research focus: Diabetes Mellitus, Type 1; Hypoglycemia; Autoimmune Diseases; Diabetes Mellitus
Sponsor: Camillo Ricordi and Jay Skyler
Countries with listed sites: No country reported
Registry dates and results: Start: 2024-06-01. Completion: 2024-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Anti-Thymocyte Globulin (ATG) (drug) — also listed as: Thymoglobulin
Interleukin 2 (drug) — also listed as: Aldesleukin; IL-2 or Proleukin®
Exenatide (drug) — also listed as: Bydureon®
Adalimumab (drug) — also listed as: HUMIRA®
ATG Placebo (other)
IL-2 Placebo (other)
Adalimumab Placebo (other)
Exenatide Placebo (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

378 matching registry records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 18:03 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableRecruitingOBSERVATIONAL

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

ClinicalTrials.gov · NCT05663515 · Registry updated: 2026-09-24

Condition / research focus: Pancreatic Cancer
Sponsor: AstraZeneca
Countries with listed sites: Denmark · Finland · France · Norway · Spain · Sweden · United Kingdom
Registry dates and results: Start: 2024-09-30. Completion: 2026-10-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: BYETTA, BYDUREON/BYDUREON BCise
Non-GLP-1 RA based glucose lowering drugs (drug) — also listed as: Insulin/analogues (excl. A10AE54, A10A56), Biguanide, Sulfonylurea, Sulfonamide (heterocycl.), combined oral GLD (excl. DPP-4i), Alpha glucose inhib., Thiazolidinedione, SGLT2i, Oth. GLD excl. insulin

Where the study takes place — 8 listed sites

Research Site
Copenhagen, Denmark
Site recruitment: Recruiting
Research Site
Helsinki, Finland
Site recruitment: Recruiting
Research Site
Paris, France
Site recruitment: Recruiting
Research Site
Bergen, Norway
Site recruitment: Recruiting
Research Site
Barcelona, Spain
Site recruitment: Recruiting
Research Site
Vänersborg, Sweden
Site recruitment: Recruiting
Research Site
Edinburgh, United Kingdom
Site recruitment: Recruiting
Research Site
London, United Kingdom
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow

ClinicalTrials.gov · NCT01988545 · Registry updated: 2026-09-15

Condition / research focus: Healthy
Sponsor: Zealand University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2013-11-01. Completion: 2014-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

1,5 nmol/kg,GLP-1 sc injection (other) — also listed as: native GLP-1
1,5 nmol/kg GLP-1 9-36amide, sc injection (other)
Exendin-4 ;10 ug,sc injection (other)
saline (other)

Where the study takes place — 1 listed sites

Køge Hospital
Køge, State..., Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization

ClinicalTrials.gov · NCT07808879 · Registry updated: 2026-09-09

Condition / research focus: Insulinoma
Sponsor: Peking Union Medical College Hospital
Countries with listed sites: China
Registry dates and results: Start: 2026-10-01. Completion: 2027-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

[68Ga]Ga-HBED-CC-PEG6-exendin-4 PET/CT (diagnostic_test) — also listed as: 68Ga-HBED-CC-PEG6-exendin-4
[68Ga]Ga-HBED-CC-exendin-4 PET/CT (diagnostic_test) — also listed as: 68Ga-HBED-CC-exendin-4

Where the study takes place — 1 listed sites

Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

ClinicalTrials.gov · NCT06725693 · Registry updated: 2026-09-08

Condition / research focus: GLP1-R-related Disease; Tumor; Insulinoma; Positron Emission Tomography
Sponsor: Tianjin Medical University
Countries with listed sites: China
Registry dates and results: Start: 2019-02-01. Completion: 2027-11-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

18F/68Ga-Exendin 4 (diagnostic_test)

Where the study takes place — 3 listed sites

The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China
Site recruitment: Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Site recruitment: Recruiting
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableActive, not recruitingOBSERVATIONAL

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

ClinicalTrials.gov · NCT05220917 · Registry updated: 2026-08-13

Condition / research focus: Cardiovascular Events; Type2 Diabetes; Renal Disease
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2021-08-01. Completion: 2027-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SGLT2 inhibitor (drug) — also listed as: CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE
DPP-4 inhibitor (drug) — also listed as: ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE
GLP-1RA (drug) — also listed as: INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE, SEMAGLUTIDE, ALBIGLUTIDE, EXENATIDE MICROSPHERES, EXENATIDE
2nd generation SU (drug) — also listed as: PIOGLITAZONE HCL/GLIMEPIRIDE, ROSIGLITAZONE MALEATE/GLIMEPIRIDE, GLIPIZIDE/METFORMIN HCL, GLYBURIDE,MICRONIZED, GLYBURIDE/METFORMIN HCL, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE

Where the study takes place — 1 listed sites

Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

ClinicalTrials.gov · NCT07702461 · Registry updated: 2026-07-24

Condition / research focus: Obesity & Overweight; Diabetes (DM)
Sponsor: Ohio State University
Countries with listed sites: United States
Registry dates and results: Start: 2026-06-12. Completion: 2027-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon-Like Peptide-1 Agonist (GLP-1) (drug) — also listed as: GLP-1RA

Where the study takes place — 1 listed sites

The Ohio State University
Columbus, Ohio, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

ClinicalTrials.gov · NCT07497399 · Registry updated: 2026-07-17

Condition / research focus: Multiple Sclerosis
Sponsor: Johns Hopkins University
Countries with listed sites: United States
Registry dates and results: Start: 2026-04-28. Completion: 2030-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NLY01 (drug)
Placebo (drug)

Where the study takes place — 2 listed sites

Johns Hopkins University
Baltimore, Maryland, United States
Site recruitment: Recruiting
Mount Sinai School of Medicine
New York, New York, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

ClinicalTrials.gov · NCT05356104 · Registry updated: 2026-06-05

Condition / research focus: Cerebral Small Vessel Disease
Sponsor: Chinese University of Hong Kong
Countries with listed sites: China · Hong Kong
Registry dates and results: Start: 2022-05-25. Completion: 2027-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug) — also listed as: Bydureon BCise, Ozempic

Where the study takes place — 2 listed sites

First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Site recruitment: Recruiting
Chinese University of Hong Kong
Hong Kong, Hong Kong
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy

ClinicalTrials.gov · NCT02860923 · Registry updated: 2026-05-22

Condition / research focus: Craniopharyngiomas; Hypothalamic Obesity
Sponsor: University Hospital, Bordeaux
Countries with listed sites: France
Registry dates and results: Start: 2017-01-11. Completion: 2018-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug)
Placebo (drug)

Where the study takes place — 11 listed sites

CHU d'Angers
Angers, France
Site recruitment: Not reported
CHU de Brest
Brest, France
Site recruitment: Not reported
CHU de Grenoble
Grenoble, France
Site recruitment: Not reported
CHU de Lyon
Lyon, France
Site recruitment: Not reported
APHM
Marseille, France
Site recruitment: Not reported
Hôpital Bicêtre
Paris, France
Site recruitment: Not reported
Hôpital Cochin
Paris, France
Site recruitment: Not reported
Hôpital Européen Georges Pompidou
Paris, France
Site recruitment: Not reported
Hôpital Pitié Salpétrière (APHP)
Paris, France
Site recruitment: Not reported
Hôpital Haut-Lévêque
Pessac, France
Site recruitment: Not reported
CHU de Toulouse
Toulouse, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics

ClinicalTrials.gov · NCT02042664 · Registry updated: 2026-05-07

Condition / research focus: Obesity; Diabetes
Sponsor: Assistance Publique Hopitaux De Marseille
Countries with listed sites: France
Registry dates and results: Start: 2011-01. Completion: 2015-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

BYETTA treatment (drug)
Metformine (drug)

Where the study takes place — 1 listed sites

Assistance Publique Hopitaux de Marseille
Marseille, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

ClinicalTrials.gov · NCT04232969 · Registry updated: 2026-05-06

Condition / research focus: Parkinson's Disease
Sponsor: University College, London
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2020-01-20. Completion: 2024-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide extended release 2mg (Bydureon) (drug)

Where the study takes place — 1 listed sites

University College London Hospital
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

ClinicalTrials.gov · NCT05482789 · Registry updated: 2026-04-20

Condition / research focus: Gestational Diabetes
Sponsor: Maisa N. Feghali, MD
Countries with listed sites: United States
Registry dates and results: Start: 2023-04-12. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug)

Where the study takes place — 1 listed sites

Magee Womens Hospital of UPMC
Pittsburgh, Pennsylvania, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3Active, not recruitingINTERVENTIONAL

Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

ClinicalTrials.gov · NCT00679042 · Registry updated: 2026-04-06

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: CellTrans Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2007-09-05. Completion: 2026-06-14 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Islets of Langerhans transplantation (biological) — also listed as: Islets of Langerhan (Islets), Basiliximab (Simulect®), Tacrolimus (Prograf®), Sirolimus (Rapamune®), Etanercept(Enbrel®), Exenatide (Byetta®)

Where the study takes place — 1 listed sites

University of Illinois at Chicago Medical Center
Chicago, Illinois, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1RecruitingINTERVENTIONAL

A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT07347080 · Registry updated: 2026-04-06

Condition / research focus: T2DM
Sponsor: The First Affiliated Hospital of Henan University of Science and Technology
Countries with listed sites: China
Registry dates and results: Start: 2026-01-20. Completion: 2026-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059）） (drug)

Where the study takes place — 1 listed sites

The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Exenatide for Smoking Cessation and Prevention of Weight Gain

ClinicalTrials.gov · NCT05610800 · Registry updated: 2026-03-23

Condition / research focus: Smoking Cessation; Weight Gain
Sponsor: The University of Texas Health Science Center, Houston
Countries with listed sites: United States
Registry dates and results: Start: 2022-12-07. Completion: 2026-03-10 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide 2 milligram (mg) Injection (drug) — also listed as: Bydureon
Placebo (drug)
Nicotine patch (drug)
Smoking Cessation Counseling (behavioral)

Where the study takes place — 2 listed sites

Michael E. DeBakey VA Medical Center
Houston, Texas, United States
Site recruitment: Not reported
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1WithdrawnINTERVENTIONAL

Exenatide For Reducing the Reinforcing Effects of Cocaine

ClinicalTrials.gov · NCT06252623 · Registry updated: 2026-03-13

Condition / research focus: Cocaine Use Disorder
Sponsor: Christopher D. Verrico
Countries with listed sites: United States
Registry dates and results: Start: 2024-08-01. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Bydureon
Placebo (drug) — also listed as: saline

Where the study takes place — 1 listed sites

Michael E. DeBakey VA Medical Center
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

ClinicalTrials.gov · NCT02251431 · Registry updated: 2026-02-19

Condition / research focus: Type 2 Diabetes Mellitus; Chronic Kidney Disease; Left Ventricular Diastolic Dysfunction
Sponsor: Baylor Research Institute
Countries with listed sites: United States
Registry dates and results: Start: 2015-11. Completion: 2019-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

BYDUREON (drug)
Placebo (drug) — also listed as: Matching placebo subcutaneous injection

Where the study takes place — 1 listed sites

Baylor Scott and White Research Institute- Baylor Heart and Vascular Hospital
Dallas, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)

ClinicalTrials.gov · NCT04897802 · Registry updated: 2026-01-20

Condition / research focus: Hypopituitarism; Central Diabetes Insipidus; Panhypopituitarism; Psychological Disorder; Social Isolation; Hypothalamic Diseases; Pituitary Diseases; Oxytocin Deficiency
Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Countries with listed sites: Spain
Registry dates and results: Start: 2021-09-13. Completion: 2024-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Experimental: GLP1-RA (exenatide) administration (drug) — also listed as: exenatide administration
Control: Placebo administration (drug) — also listed as: placebo administration (sodium chloride)

Where the study takes place — 1 listed sites

Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Clinical Study of 18F-Exendin-4 in Insulinoma

ClinicalTrials.gov · NCT07340437 · Registry updated: 2026-01-15

Condition / research focus: Insulinoma
Sponsor: Sichuan Provincial People's Hospital
Countries with listed sites: China
Registry dates and results: Start: 2023-02-01. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Department of Endocrinology and Department of Nuclear Medicine, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072
Chengdu, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2WithdrawnINTERVENTIONAL

Diabetes Islet Preservation Immune Treatment

ClinicalTrials.gov · NCT02586831 · Registry updated: 2026-01-15

Condition / research focus: Diabetes Mellitus, Type 1; Hypoglycemia; Autoimmune Diseases; Diabetes Mellitus
Sponsor: Camillo Ricordi and Jay Skyler
Countries with listed sites: No country reported
Registry dates and results: Start: 2024-06-01. Completion: 2024-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Anti-Thymocyte Globulin (ATG) (drug) — also listed as: Thymoglobulin
Interleukin 2 (drug) — also listed as: Aldesleukin; IL-2 or Proleukin®
Exenatide (drug) — also listed as: Bydureon®
Adalimumab (drug) — also listed as: HUMIRA®
ATG Placebo (other)
IL-2 Placebo (other)
Adalimumab Placebo (other)
Exenatide Placebo (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →